Satraplatin
-
Satraplatin
structure -
-
CAS No:
129580-63-8
-
Formula:
C10H22Cl2N2O4Pt
-
Chemical Name:
Satraplatin
-
Synonyms:
Platinum,bis(acetato-κO)amminedichloro(cyclohexanamine)-,(OC-6-43)-;Platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43)-;Cyclohexanamine,platinum complex;JM 216;Satraplatin;BMY 45594;POplat;BMS 182751;367265-85-8
-
CAS No:
Description
ChEBI: A platinum coordination entity that consists of a central platunum atom bound to chloro (x2), acetate (x2), amino, and cyclohexylamino groups. Used for treatment of advanced prostate cancer.
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
Characteristics
102
3.70610
134.5ºCat 760 mmHg
32.2ºC
0.4
LD50 in mice (mg/kg): 30 i.p.; 330 orally (Kelland)
Drug Information
Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors.
This drug binds to the DNA of cancer cells, inhibiting cell division.
Satraplatin Use and Manufacturing
Antineoplastic.Satraplatin (JM216, cis,trans,cis-[PtCl2(OAc)2(NH3)(C6H5NH2)]) is a Pt(IV) or Pt4+ complex, which is active by oral administration, as it is more hydrophobic than cisplatin. This form of administration is very attractive because of the convenience and freedom it provides to the patient. Satraplatin also has a milder toxicity profile and is shows no cross-resistance with cisplatin. Satraplatin in combination with prednisone has completed phase III clinical trials against hormone-r